Training components for GCP. inspectors in PMDA. Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA

Similar documents
Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan

GCP Inspection by PMDA

Dr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015

General Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility

Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol

ETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM

Auditing of Clinical Trials

Why do we need an addendum to ICH E6?

STANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager

Standard Operating Procedure (SOP) Research and Development Office

Research Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004

Standard Operating Procedures

Audit and Inspection

Ethics Committee Composition Roles & Responsibilities. Dr Girish Dayma Dr Sanjay Juvekar KEM Hospital Research Centre Pune

CLIC Clinical Investigator (And Site Staff) Certification

MHRA Findings Dissemination Joint Office Launch Jan Presented by: Carolyn Maloney UHL R&D Manager

Introduction to the United States Food and Drug Administration (FDA) and FDA Inspection Process VOICE

Roles & Responsibilities of Investigator & IRB

Margaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance

Research Audits PGR. Effective: 12/04/2013 Reviewed: 12/04/2015. Name of Associated Policy: Palmetto Health Administrative Research Review

Overview of the IMB s. Good Clinical Practice. Deirdre O Regan GCP/Pharmacovigilance. GCP Seminar Dublin, 27 th January 2010.

Good Documentation Practices. Human Subject Research. for

Standard Operating Procedure (SOP) Research and Development Office

First inspection of a Legal Representative in the EU by local authority

Trial Management: Trial Master Files and Investigator Site Files

Document Title: Informed Consent for Research Studies

Regulatory Inspections

Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics Oslo

ISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan

Documenting the Story of a Clinical Trial: Concept to CAPA. Lori T. Gilmartin Gilmartin Consulting LLC

LOUIS STOKES CLEVELAND VA MEDICAL CENTER RESEARCH SERVICE Human Subject Protection Standard Operating Procedure (SOP)

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV)

Document Title: Document Number:

Standard Operating Procedure (SOP) for Reporting Serious Breaches in Clinical Research

SOP: New Revised Reviewed Effective Date: 08 October Approved by : Supervisor/Manager Risk/Ethics Sr. Mgmt Committees Board/Councils

NN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION

AN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES

Overview ICH GCP E6(R2) Integrated Addendum

New European Union Clinical Trial Regulations

Standard Operating Procedure. Essential Documents: Setting Up a Trial Master File. SOP effective: 19 February 2016 Review date: 19 February 2018

GCP: Investigator Responsibilities. Susan Tebbs Nicola Kaganson

managing or activities.

STANDARD OPERATING PROCEDURE

SOP-QA-28 V2. Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head of School

Solutions for GCP Compliance Challenges. September 23, 2015 Northwestern University IRB Brown Bag Session

Solutions for GCP Compliance Challenges

Joint Statement on the Application of Good Clinical Practice to Training for Researchers

Good Clinical Practice: A Ground Level View

BIMO SITE AUDIT CHECKLIST

Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026

Comprehensive Protocol Feasibility Questionnaire

Document Number: 006. Version: 1. Date ratified: Name of originator/author: Heidi Saunders, Senior Portfolio Coordinator

The GCP Perspective on Study Monitoring

Site Qualification and Training (SQT) INFORMATION AND GUIDANCE SHEET FOR SITE SIGNATURE AND DELEGATION OF RESPONSIBILITIES LOG

VCU Clinical Research Quality Assurance Assessment

Japanese submission/approval processes from programming perspective Ryan Hara, Novartis Pharma AG, Basel, Switzerland

Audits/Inspections Be Prepared for Anything

Quality Assurance and Regulatory Compliance Office and USAMRIID FDA Risk Management. Carolyn Mentzer Chief, QARCO

Investigator-Initiated Studies: When you re the Sponsor. Cheri Robert & Tammy Mah-Fraser

QUALITY ASSURANCE PROGRAM

Sponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law

Successful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics

Toward Greater Scientific Rigor

Document Title: GCP Training for Research Staff. Document Number: SOP 005

12.0 Investigator Responsibilities

Session 3 FDA Audits and Findings

Course program. Good Clinical Practice (GCP) course for surgeons

FDA Inspection Readiness

Clinical Trial Quality Assurance Common Findings

GCP INSPECTION CHECKLIST

Document Title: Study Data SOP (CRFs and Source Data)

Work plan for GCP Inspectors Working Group for 2018

Document Title: Investigator Site File. Document Number: 019

FDA Inspectional Process in Clinical Research An FDA Perspective. Annette Melendez, MPHsN Investigator Office of Biological Products Operations

EMA & FDA Inspections: Site perspective. Shandukani Research Centre

Training, Site Selection and Human Subject Protection: Factors to Consider When Developing a Monitoring Plan

Conducting Monitoring Visits for Investigator-Initiated Trials (IITs)

Addendum to ICH E6 (R2)

Clinical Trial Readiness Checklist October 2014

Research Staff Training

Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust

Site Closedown Checklist for UoL Sponsored CTIMP Studies

Standard Operating Procedures

FDA Medical Device Regulations vs. ISO 14155

Office of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators

MARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: MCCCRO-D

COMPETENCY FRAMEWORK

Version Number: 004 Controlled Document Sponsor: Controlled Document Lead:

Document Title: Research Database Application (ReDA) Document Number: 043

Mid-term Targets of the Pharmaceuticals and Medical Devices Agency (PMDA) *(Provisional Translation)

MANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

DEPARTMENT OF HEALTH & HUMAN SERVICES WARNING LETTER. (b) (4) clinical investigation (Protocol entitled A Phase II, Multicenter,

CQA Consultant of HVCC, Hilversum, the Netherlands. Coaching of auditors on various levels is an on-going activity.

Document Title: Recruiting Process. Document Number: 011

Take a Course of Action.

PLATELET-ORIENTED INHIBITION ISCHEMIC STROKE (POINT) MONITORING PLAN IN NEW TIA AND MINOR. Version 2.0 Updated 11 May 2017

PMDA EPOCH Toward 2020

Document Title: Research Database Application (ReDA) Document Number: 043

Research & Development Quality Manual

Transcription:

Training components for GCP inspectors in PMDA Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA

Content 1. Conformity inspection in the training program for newcomers to PMDA 2. The training programs for new members of the conformity audit office 3. The training programs for foreign regulatory officers Pharmaceuticals and Medical Devices Agency 2

PMDA Staff Size

Training program for newcomers to PMDA Intended for all newcomers including GCP inspectors. Consisting of lectures and case studies. Covering broad topics such as process of drug development, review and approval process, GCP and related regulations and guidelines, post-marketing safety measures, etc. Taking about 30 days to finish the program. Conformity inspection and GXP for data integrity are important topics in the program.

Conformity inspection in the program (1) Introducing the concept of GCP and the pharmaceutical affairs act. Ethical and scientific quality standard for designing, conducting, recording, and reporting trials. Presenting data integrity standards for product applications. Accuracy: Accurate preparation of dossier based on the results of analyses and studies Completeness: Description of results which cast no doubt on quality, efficacy or safety Retention: Retention of the original data

Conformity inspection in the program (2) Major activities in the Office of Conformity Audit Consultation Before application Inspection Application-based Enlightening activities GCP workshop with sponsors, medical institutions, CRO, SMO, etc. Promoting international activities

Conformity inspection in the program (3) Case study from the Office of Conformity Audit Informed consent Vulnerable subjects The role of a CRC/witness in taking the IC Institution Review Board Composition of IRB members Selection of subjects Deviation from the exclusion criteria

Content 1. Conformity inspection in the training program for newcomers to PMDA 2. The training programs for new members of the conformity audit office 3. The training programs for foreign regulatory officers Pharmaceuticals and Medical Devices Agency

Office of Conformity Audit, PMDA Office Director Office Deputy Director GCP On-site Inspection (Drugs team:21) (Devices team:7) Document -based Conformity Inspection (Drugs team:16) (Devices team:7) GLP Inspection (6) GPSP Inspection (13) ( ): The number of inspectors

Training program in Conformity Audit office OJT (On the Job Training) is the main role. Inspectors are trained/educated by their mentors Checklists for on-site inspection are used as a reference Preparation for the inspection Inspecting procedures Reporting the inspection results in the office meeting is a good chance to train/educate inspector GCP workshop held yearly offers a learning opportunity Intended participants (Sponsors, Medical institutions, CROs, SMOs, etc.) Provide information on inspection (Purpose, Points to consider, Findings in recent inspections, etc.)

Checklist Utilization Objective Inspectors can cover what they should review at least. Every inspector can review in the same way. Medical institution and/or sponsor can prepare for the inspection.

[ I ] Outline of the Medical Institution Preparing the SOPs for clinical trial Checklist for the Institution (Investigator, IRB, and Head of the Institution) [ II ] IRB Using local IRB or other IRB Preparing the SOPs, membership list, and minutes of meetings of the IRB Composition of the IRB comply with GCP. (ex:at least five members, at least one member who is independent of the inst itution/trial site, etc. ) Conducting continuing review of each ongoing trial at least once per year Reviewing all SAE reports from the investigator and safety reports from the sponsor appropriately [ III ] Principal investigator Preparing a list of the sub-investigators and the coordinators [ IV ] Clinical trial management All SAEs were reported to the sponsor, the IRB, head of the medical institution PI documented any deviation from the protocol The investigational product(s) were stored appropriately [V] Informed consent The written informed consent form includes necessary matters Selections of the subjects are applicable [ VI ] Case report form Preparing accurate CRFs and signed by PI

Excerpt from the Checklist (Institution) II-3. Composition of the IRB [Art. 28, para. 1] In compliance Capable of sufficient review the ethics and science Apr.98~ Consisting of at least 5 members At least one member whose primary area of interest is in a nonscientific area. At least one member who is independent of the institution/trial site.

Conclusion of GCP On-site Inspection Compliance: Acceptable as application dossier (indicate voluntary action, if necessary) Compliance with condition: Violation of GCP was found in a part of subjects Acceptable as application dossier after excluding the data from NDA package Non-compliance: Violation of GCP was found generally and systematically No reliability Not acceptable as application dossier

Content 1. Conformity inspection in the training program for newcomers to PMDA 2. The training programs for new members of the conformity audit office 3. The training programs for foreign regulatory officers Pharmaceuticals and Medical Devices Agency

PMDA International Strategic Plan (February, 2009) Strengthening of cooperation and building of collaborative relations with the United S tates (US), the European Union (EU), Asian countries, and relevant international organi zations

Thank you for your attention! Please contact us. http://www.pmda.go.jp/